PMC:7502678 / 8395-11918
Annnotations
LitCovid-PD-FMA-UBERON
Id | Subject | Object | Predicate | Lexical cue | fma_id |
---|---|---|---|---|---|
T4 | 1025-1036 | Body_part | denotes | vagus nerve | http://purl.org/sig/ont/fma/fma5731 |
LitCovid-PD-UBERON
Id | Subject | Object | Predicate | Lexical cue | uberon_id |
---|---|---|---|---|---|
T4 | 1025-1036 | Body_part | denotes | vagus nerve | http://purl.obolibrary.org/obo/UBERON_0001759 |
T5 | 1031-1036 | Body_part | denotes | nerve | http://purl.obolibrary.org/obo/UBERON_0001021 |
LitCovid-PD-MONDO
Id | Subject | Object | Predicate | Lexical cue | mondo_id |
---|---|---|---|---|---|
T42 | 762-765 | Disease | denotes | CMS | http://purl.obolibrary.org/obo/MONDO_0018940 |
T43 | 991-999 | Disease | denotes | epilepsy | http://purl.obolibrary.org/obo/MONDO_0005027 |
T44 | 1276-1284 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T45 | 1665-1673 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T46 | 1707-1716 | Disease | denotes | infection | http://purl.obolibrary.org/obo/MONDO_0005550 |
T47 | 2167-2175 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T48 | 2230-2238 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T49 | 2373-2376 | Disease | denotes | ASM | http://purl.obolibrary.org/obo/MONDO_0020333 |
T50 | 2408-2416 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T51 | 3064-3072 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
LitCovid-PD-CLO
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T37 | 56-57 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | A |
T38 | 208-215 | http://purl.obolibrary.org/obo/UBERON_0000473 | denotes | testing |
T39 | 1031-1036 | http://purl.obolibrary.org/obo/UBERON_0001021 | denotes | nerve |
T40 | 1312-1313 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
T41 | 1752-1753 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
T42 | 1763-1765 | http://purl.obolibrary.org/obo/CLO_0050507 | denotes | 22 |
T43 | 3189-3192 | http://purl.obolibrary.org/obo/CLO_0051582 | denotes | has |
LitCovid-PD-CHEBI
Id | Subject | Object | Predicate | Lexical cue | chebi_id |
---|---|---|---|---|---|
T6 | 779-782 | Chemical | denotes | EEG | http://purl.obolibrary.org/obo/CHEBI_73494 |
T7 | 1892-1895 | Chemical | denotes | EEG | http://purl.obolibrary.org/obo/CHEBI_73494 |
T8 | 2071-2076 | Chemical | denotes | group | http://purl.obolibrary.org/obo/CHEBI_24433 |
T9 | 2207-2210 | Chemical | denotes | EEG | http://purl.obolibrary.org/obo/CHEBI_73494 |
T10 | 2582-2595 | Chemical | denotes | levetiracetam | http://purl.obolibrary.org/obo/CHEBI_6437 |
T11 | 2600-2609 | Chemical | denotes | midazolam | http://purl.obolibrary.org/obo/CHEBI_6931 |
T12 | 2642-2644 | Chemical | denotes | IV | http://purl.obolibrary.org/obo/CHEBI_74327 |
T13 | 2645-2660 | Chemical | denotes | benzodiazepines | http://purl.obolibrary.org/obo/CHEBI_22720 |
T14 | 2962-2964 | Chemical | denotes | IV | http://purl.obolibrary.org/obo/CHEBI_74327 |
LitCovid-PubTator
Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
---|---|---|---|---|---|
145 | 633-640 | Species | denotes | patient | Tax:9606 |
151 | 1018-1022 | Species | denotes | EMUs | Tax:8790 |
152 | 949-954 | Disease | denotes | COVID | MESH:C000657245 |
153 | 991-999 | Disease | denotes | epilepsy | MESH:D004827 |
154 | 1206-1211 | Disease | denotes | COVID | MESH:C000657245 |
155 | 1276-1284 | Disease | denotes | COVID-19 | MESH:C000657245 |
161 | 1626-1634 | Species | denotes | patients | Tax:9606 |
162 | 1968-1972 | Species | denotes | EMUs | Tax:8790 |
163 | 1665-1673 | Disease | denotes | COVID-19 | MESH:C000657245 |
164 | 1707-1716 | Disease | denotes | infection | MESH:D007239 |
165 | 2167-2175 | Disease | denotes | COVID-19 | MESH:C000657245 |
167 | 2230-2238 | Disease | denotes | COVID-19 | MESH:C000657245 |
174 | 2952-2960 | Species | denotes | patients | Tax:9606 |
175 | 2582-2595 | Chemical | denotes | levetiracetam | MESH:D000077287 |
176 | 2600-2609 | Chemical | denotes | midazolam | MESH:D008874 |
177 | 2645-2660 | Chemical | denotes | benzodiazepines | MESH:D001569 |
178 | 2352-2359 | Disease | denotes | seizure | MESH:D012640 |
179 | 2408-2416 | Disease | denotes | COVID-19 | MESH:C000657245 |
181 | 3064-3072 | Disease | denotes | COVID-19 | MESH:C000657245 |
183 | 3249-3256 | Species | denotes | patient | Tax:9606 |
LitCovid-PD-HP
Id | Subject | Object | Predicate | Lexical cue | hp_id |
---|---|---|---|---|---|
T34 | 991-999 | Phenotype | denotes | epilepsy | http://purl.obolibrary.org/obo/HP_0001250 |
T35 | 2352-2359 | Phenotype | denotes | seizure | http://purl.obolibrary.org/obo/HP_0001250 |
LitCovid-PD-GO-BP
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T4 | 3404-3412 | http://purl.obolibrary.org/obo/GO_0007612 | denotes | learning |
LitCovid-sentences
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T74 | 0-27 | Sentence | denotes | Impact on Clinical Practice |
T75 | 29-55 | Sentence | denotes | Barriers to Providing Care |
T76 | 56-128 | Sentence | denotes | A range of barriers were reported in providing care during the pandemic. |
T77 | 129-269 | Sentence | denotes | Most frequently noted were limited access to in-person visits and nonemergency testing reported by 74% and 66% of respondents, respectively. |
T78 | 270-488 | Sentence | denotes | Provider fear related to the outbreak and concern for their own well-being was reported by nearly 30%, while lack of personal protective equipment (PPE) and financial considerations were reported by 25% of respondents. |
T79 | 489-572 | Sentence | denotes | Technological problems for telehealth visits were noted in only 15% of respondents. |
T80 | 573-666 | Sentence | denotes | Only 7% of respondents experienced no barriers in providing patient care during the pandemic. |
T81 | 667-837 | Sentence | denotes | One respondent noted that between the pandemic and Centers for Medicare and Medicaid Services (CMS) cutbacks on EEG reimbursement, continuing practice appeared difficult. |
T82 | 838-1213 | Sentence | denotes | Respondents also cited the following additional practice-related barriers to providing care: prioritization of COVID over nonurgent care; suspensions of epilepsy monitoring units (EMUs), vagus nerve stimulator implantations, and presurgical evaluation and surgery; reopening logistics; staff cuts; and clinic staffing (eg, childcare challenges and fear of exposure to COVID). |
T83 | 1214-1411 | Sentence | denotes | Regarding when respondents expected to return services to pre-COVID-19 levels, the answers formed a normally distributed Bell-shaped curve between now and never, centered at approximately 6 months. |
T84 | 1412-1449 | Sentence | denotes | Only 9% of respondents were not sure. |
T85 | 1450-1523 | Sentence | denotes | Approximately 5% did not feel their practice would ever return to normal. |
T86 | 1525-1553 | Sentence | denotes | Neurophysiologic Evaluations |
T87 | 1554-1717 | Sentence | denotes | About half of respondents (47%) reported that EEGs were discouraged for patients admitted to the hospital with COVID-19 or those suspected of having the infection. |
T88 | 1718-1829 | Sentence | denotes | Even without restrictions, nearly a quarter (22%) reported they were doing fewer studies than usual (Figure 4). |
T89 | 1830-1907 | Sentence | denotes | About 9% responded they were no longer doing continuous video-EEG monitoring. |
T90 | 1908-1984 | Sentence | denotes | In the write in comments, many respondents noted that their EMUs had closed. |
T91 | 1985-2185 | Sentence | denotes | Very few respondents (2%) reported that they were doing more EEGs than usual; of this group, 5 were from institutions where there were no restrictions for performing EEGs during the COVID-19 pandemic. |
T92 | 2186-2195 | Sentence | denotes | Figure 4. |
T93 | 2197-2248 | Sentence | denotes | Inpatient EEG utilization during COVID-19 pandemic. |
T94 | 2250-2286 | Sentence | denotes | Medication Interactions or Shortages |
T95 | 2287-2417 | Sentence | denotes | Almost no respondents had seen unusual interactions between anti-seizure medications (ASM) and medications used to treat COVID-19. |
T96 | 2418-2498 | Sentence | denotes | Medications shortages were noted by approximately 44% of respondents (Figure 5). |
T97 | 2499-2692 | Sentence | denotes | In write-in comments, the most frequently noted shortages were of extended release levetiracetam and midazolam, and other shortages of several IV benzodiazepines were noted by some respondents. |
T98 | 2693-2772 | Sentence | denotes | However, it appears some of these shortages existed from prior to the pandemic. |
T99 | 2773-2902 | Sentence | denotes | By and large, there appeared to be no consistent pattern of shortages of conventional ASMs directly attributable to the pandemic. |
T100 | 2903-3024 | Sentence | denotes | The majority of shortage reports originated from patients; IV anesthetic shortages were reported by inpatient pharmacies. |
T101 | 3025-3034 | Sentence | denotes | Figure 5. |
T102 | 3036-3082 | Sentence | denotes | Medication shortages during COVID-19 pandemic. |
T103 | 3084-3102 | Sentence | denotes | Impact on Trainees |
T104 | 3103-3229 | Sentence | denotes | Trainees (residents and fellows) responded in low numbers and noted that the pandemic has harmed their educational experience. |
T105 | 3230-3309 | Sentence | denotes | They cited reduced patient volumes and canceled clinics as responsible factors. |
T106 | 3310-3523 | Sentence | denotes | Furthermore, the cancelling of interprofessional conferences and educational meetings limited learning and networking opportunities outside the home institution as well as the opportunity to present academic work. |